Ticker > Company >

Auro Laboratories share price

Auro Laboratories Ltd.

BSE: 530233 SECTOR: Pharmaceuticals & Drugs  30.6 K   204   13

195.50
-1.80 (-0.91%)
BSE: 04 Nov 4:00 PM

Price Summary

Today's High

₹ 199.5

Today's Low

₹ 185

52 Week High

₹ 303

52 Week Low

₹ 170

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

121.85 Cr.

Enterprise Value

166.23 Cr.

No. of Shares

0.62 Cr.

P/E

174.07

P/B

2.84

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  68.77

CASH

0.63 Cr.

DEBT

45.01 Cr.

Promoter Holding

52.18 %

EPS (TTM)

₹  1.12

Sales Growth

-63.83%

ROE

4.33 %

ROCE

3.79%

Profit Growth

-76.4 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-63.83%
3 Year-27.48%
5 Year-15.03%

Profit Growth

1 Year-76.4%
3 Year-13.54%
5 Year-14.63%

ROE%

1 Year4.33%
3 Year10.74%
5 Year14.07%

ROCE %

1 Year3.79%
3 Year11.36%
5 Year17.03%

Debt/Equity

1.0476

Price to Cash Flow

21.2

Interest Cover Ratio

2.7377

CFO/PAT (5 Yr. Avg.)

1.54141666959957

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 52.18 0.00
Jun 2025 52.18 0.00
Mar 2025 52.18 0.00
Dec 2024 52.15 0.00
Sep 2024 52.15 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 80.2369 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.54141666959957.
  • The company has a high promoter holding of 52.18%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 37.7011623654537.

 Limitations

  • The company has shown a poor profit growth of -13.5370816297812% for the Past 3 years.
  • The company has shown a poor revenue growth of -27.4816235422197% for the Past 3 years.
  • Company has high debtor days of 214.3696.
  • The company is trading at a high PE of 174.07.
  • The company is trading at a high EV/EBITDA of 55.2627.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 5.72 3.1 3.06 7.4 2.77
Total Expenditure 4.4 2.38 2.61 6.59 2.74
Operating Profit 1.32 0.72 0.44 0.81 0.03
Other Income 0.2 0.31 0.14 0.13 0.42
Interest 0.25 0.28 0.25 0.3 0.28
Depreciation 0.27 0.27 0.27 0.29 0.27
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.01 0.48 0.07 0.35 -0.11
Tax 0.25 0.12 0.02 -0.04 0
Profit After Tax 0.75 0.36 0.05 0.4 -0.11
Adjusted EPS (Rs) 1.21 0.58 0.08 0.63 -0.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 54.25 50.87 52.89 53.64 19.4
Total Expenditure 43.01 46.24 48.5 42.97 15.99
Operating Profit 11.24 4.63 4.39 10.67 3.4
Other Income 0.76 1.09 0.94 1.5 0.66
Interest 0.46 0.83 0.81 0.74 1.08
Depreciation 1.04 1.02 1.07 1.09 1.1
Exceptional Items 0 0 0 0 0
Profit Before Tax 10.51 3.87 3.45 10.35 1.88
Tax 3.33 1.03 1 2.55 0.04
Net Profit 7.18 2.84 2.44 7.79 1.84
Adjusted EPS (Rs.) 11.52 4.56 3.92 12.5 2.95

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 6.23 6.23 6.23 6.23 6.23
Total Reserves 22.35 25.29 27.97 35.73 36.74
Borrowings 2.39 1.66 2.01 18.38 33.09
Other N/C liabilities 1.68 1.65 1.65 1.46 1.4
Current liabilities 9.24 20.13 18.13 23.93 21.64
Total Liabilities 41.89 54.96 55.99 85.73 99.1
Assets
Net Block 13.56 13.61 12.62 22.15 21.06
Capital WIP 0.13 3.68 7.67 32.68 56.48
Intangible WIP 0 0 0 0 0
Investments 0.05 0.05 0.05 0.05 0.05
Loans & Advances 0.2 0.28 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 27.96 37.35 35.66 30.85 21.51
Total Assets 41.89 54.96 55.99 85.73 99.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 10.51 3.87 3.45 10.35 1.88
Adjustment 1.33 1.6 2.13 2.08 1.9
Changes in Assets & Liabilities 0.98 -12.07 -2.3 6.38 1.96
Tax Paid 0 0 0 0 0
Operating Cash Flow 12.82 -6.59 3.28 18.81 5.75
Investing Cash Flow -3.51 -5.34 -5.08 -38.67 -24.45
Financing Cash Flow -0.46 9.79 -8.18 19.09 17.69
Net Cash Flow 8.85 -2.14 -9.98 -0.77 -1.02

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 52.15 52.15 52.18 52.18 52.18
auro impex private ltd 18.75 18.75 18.75 18.75 18.75
samridhi deorah 3.87 3.87 3.87 3.87 3.87
sharat deorah 18.71 18.71 18.71 18.71 18.71
sharat deorah huf 3.67 3.67 3.67 3.67 3.67
siddhartha deorah 7.09 7.09 7.09 7.09 7.09
siddhartha deorah huf 0.06 0.06 0.09 0.09 0.09
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 47.85 47.85 47.82 47.82 47.82
kirtilaben jayantilal meh... 3.13 - 3.13 3.13 3.13
llp 0.07 - 0.08 0.07 0.08
ravi parimal shah 1.45 1.45 1.45 1.45 1.45
samir jitendra javeri - - - - 1.70
shikha lohia 1.54 1.54 - 1.54 1.54
ushma gautam doshi - 1.35 1.46 1.36 -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit ICRA
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Auro Laboratories - Quaterly Results 14 Aug, 7:18 PM Auro Laboratories - Quaterly Results 14 Aug, 7:18 PM Auro Laboratories informs about disclosure 4 Mar, 4:41 PM Auro Laboratories informs about disclosure 25 Feb, 1:05 PM Auro Laboratories informs about disclosure 24 Feb, 5:20 PM Auro Laboratories informs about disclosure 24 Feb, 4:43 PM Auro Laboratories informs about disclosures 21 Feb, 6:19 PM Auro Laboratories informs about disclosure 21 Feb, 12:29 PM Auro Laboratories - Quaterly Results 14 Feb, 5:45 PM Auro Laboratories - Quaterly Results 11 Nov, 7:50 PM Auro Laboratories - Quaterly Results 11 Nov, 7:50 PM Auro Laboratories - Quaterly Results 9 Aug, 6:19 PM Auro Laboratories - Quaterly Results 9 Aug, 6:19 PM Auro Laboratories informs about issuance of duplicate share certificate 20 Jun, 5:19 PM Auro Laboratories informs about press release 27 May, 5:28 PM Auro Laboratories - Quaterly Results 25 May, 9:55 PM Auro Laboratories informs about disclosure 22 Mar, 1:00 PM Auro Laboratories informs about loss of share certificates 6 Mar, 3:58 PM Auro Laboratories - Quaterly Results 6 Feb, 5:41 PM Auro Laboratories - Quaterly Results 6 Feb, 5:41 PM Auro Laboratories - Quaterly Results 6 Feb, 5:41 PM Auro Laboratories inks pact with MIDC 25 Jan, 10:30 AM Auro Laboratories gets nod for capacity expansion 23 Aug, 5:16 PM Auro Laboratories - Quaterly Results 31 Jul, 4:17 PM Auro Laboratories - Quaterly Results 31 Jul, 4:17 PM Auro Laboratories - Quaterly Results 31 Jul, 4:17 PM Auro Laboratories informs about financial results 16 May, 4:58 PM Auro Laboratories - Quaterly Results 16 May, 4:02 PM Auro Laboratories - Quaterly Results 16 May, 4:02 PM Auro Laboratories - Quaterly Results 16 May, 4:02 PM Auro Laboratories informs about certificate 18 Apr, 5:06 PM Auro Laboratories informs about certificate 18 Apr, 5:04 PM Auro Laboratories informs about compliance certificate 18 Apr, 4:31 PM Auro Laboratories - Quaterly Results 13 Feb, 4:11 PM Auro Laboratories - Quaterly Results 13 Feb, 4:11 PM Auro Laboratories informs about newspaper cuttings 3 Aug, 12:16 PM Auro Laboratories - Quaterly Results 2 Aug, 3:24 PM Auro Laboratories - Quaterly Results 2 Aug, 3:24 PM Auro Laboratories - Quaterly Results 2 Aug, 3:24 PM Auro Laboratories informs about closure of trading window 28 Jun, 12:49 PM Auro Laboratories informs about newspaper cuttings 25 Jun, 12:51 PM Auro Laboratories informs about newspaper publications 31 May, 1:09 PM Auro Laboratories informs about secretarial compliance report 30 May, 3:54 PM Auro Laboratories informs about compliance certificate 8 Apr, 4:38 PM Auro Laboratories Informs about disclosures 1 Apr, 4:19 PM Auro Laboratories informs about disclosure 16 Dec, 1:09 PM Auro Laboratories informs about newspaper publication 12 Nov, 2:07 PM Auro Laboratories informs about compliance certificate 7 Oct, 9:44 AM Auro Laboratories informs about disclosure 20 Sep, 11:38 AM Auro Laboratories informs about press release 18 Feb, 12:41 PM

Auro Laboratories Stock Price Analysis and Quick Research Report. Is Auro Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Auro Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Auro Laboratories has a PE ratio of 174.071765648651 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Auro Laboratories has ROA of 1.9896% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Auro Laboratories has a Current ratio of 0.9941.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Auro Laboratories has a ROE of 4.3301%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Auro Laboratories has a Debt to Equity ratio of 1.0476 which means that the company has low proportion of debt in its capital.

  • Sales growth: Auro Laboratories has reported revenue growth of -63.8327% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Auro Laboratories for the current financial year is 17.5452614648631%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Auro Laboratories is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Auro Laboratories is Rs 1.1231. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Auro Laboratories in Ticker for free. Also, one can get the intrinsic value of Auro Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Auro Laboratories FAQs

Q1. What is Auro Laboratories share price today?
Ans: The current share price of Auro Laboratories is Rs 195.5.

Q2. What is the market capitalisation of Auro Laboratories?
Ans: Auro Laboratories has a market capitalisation of Rs 121.845375 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Auro Laboratories?
Ans: The PE ratio of Auro Laboratories is 174.071765648651 and the P/B ratio of Auro Laboratories is 2.8426646891608, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Auro Laboratories share?
Ans: The 52-week high share price of Auro Laboratories is Rs 303, and the 52-week low share price of Auro Laboratories is Rs 170.

Q5. Does Auro Laboratories pay dividends?
Ans: Currently, Auro Laboratories does not pay dividends. Dividend yield of Auro Laboratories is around 0%.

Q6. What are the face value and book value of Auro Laboratories shares?
Ans: The face value of Auro Laboratories shares is Rs 10, while the book value per share of Auro Laboratories is around Rs 68.7735. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Auro Laboratories?
Ans: Auro Laboratories has a total debt of Rs 45.0144 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Auro Laboratories?
Ans: The ROE of Auro Laboratories is 4.3301% and ROCE of Auro Laboratories is 3.7946%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Auro Laboratories a good buy for the long term?
Ans: The Auro Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Auro Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Auro Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Auro Laboratories’s financials?
Ans: You can review Auro Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Auro Laboratories
X